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Determination of Risk Factors Associated With Isolation
of Linezolid-Resistant Strains of Vancomycin-Resistant Enterococcus
Jason M. Pogue, PharmD; David L. Paterson, MD; A. William Pasculle, ScD; Brian A. Potoski, PharmD
objective. To identify independent risk factors associated with isolation of linezolid-resistant, vancomycin-resistant Enterococcus (VRE).
design. A retrospective, case-case-control study.
setting. A tertiary care, academic medical center.
methods. VRE isolates from clinical cultures were retrospectively analyzed for linezolid resistance during our 18-month study period.
Clinical data were obtained from electronic patient records, and the risk factors associated with isolation of linezolid-resistant VRE were
determined by comparison of 2 case groups with a control group.
results. A total of 20% of the VRE isolates analyzed during the study period were linezolid resistant, and resistant isolates were most
commonly recovered from the urine (40% of resistant isolates). Risk factors found to be associated with isolation of linezolid-resistant
VRE were peripheral vascular disease and/or the receipt of a solid organ transplant, total parenteral nutrition, piperacillin-tazobactam, and/
or cefepime. Only 25% of patients from whom linezolid-resistant VRE was isolated had previous linezolid exposure, and in the multivariate
model this was not found to be a risk factor associated with the isolation of linezolid-resistant VRE.
conclusions. The results of this analysis suggest that there is horizontal transmission of linezolid-resistant VRE in our institution and
highlight the need for improved infection control measures. Furthermore, the high incidence of linezolid-resistant VRE demands a reas-
sessment of our empirical antibiotic selection for patients infected with VRE.
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Linezolid, an oxazolidione antimicrobial, has been an essen-
tial agent in the treatment of infections due to multidrug-
resistant, gram-positive organisms, including vancomycin-re-
sistant Enterococcus (VRE). Linezolid resistance in VRE,
although relatively uncommon, was initially associated with
prolonged exposure to linezolid.1-6 However, more recently,
linezolid-resistant VRE has been isolated from patients who
did not have prior antimicrobial exposure, which is more
consistent with horizontal transmission of the organism.5,7-12
Furthermore, newer data document a much higher prevalence
of linezolid-resistant organisms—11% to 17%—recovered
from patients colonized or infected with VRE.3,10
In our institution we have noted high rates of linezolid
resistance among enterococcal isolates. Although enterococci
have a relative lack of virulence, bloodstream infections and
other sterile-site infections due to resistant strains are asso-
ciated with significant morbidity, and inadequate empirical
antimicrobial therapy for enterococcal sepsis is associated
with increased hospital mortality.13,14 Furthermore, patients
with enterococcal bloodstream infections have high rates of
both septic shock and organ failure.15 Determination of the
risk factors associated with isolation of linezolid-resistant
VRE may help identify and prevent infections due to this
organism. We therefore designed this retrospective, case-case-
control study in an attempt to elucidate any such risk factors.
methods
This study was approved as a quality improvement study by
the Total Quality Council of the University of Pittsburgh
Medical Center, Presbyterian Hospital.
Susceptibility Testing
Linezolid susceptibility was determined using disk diffusion
methodology, as recommended by the Clinical and Labora-
tory Standards Institute (CLSI).16 This testing was routinely
performed by our hospital’s clinical microbiology laboratory
on all enterococcal isolates.
Institutional Antimicrobial Use
Pharmacy records were reviewed to determine the aggregate
use of linezolid in the hospital during the study time frame.
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table 1. Demographic Characteristics of Patients in the 2 Case
Groups and the Control Group
Characteristic
Resistant
case group
(N p 63)
Susceptible
case group
(N p 63)
Control
group
(N p 126)
Sex
Male 29 (46) 26 (41) 69 (55)
Female 34 (54) 37 (59) 57 (45)
Race
White 51 (81) 50 (79) 99 (79)
African American 7 (11) 8 (13) 15 (12)
Other 5 (8) 5 (8) 12 (9)
Age, median (range), years 59 (20-95) 61 (20-85) 59 (14-89)
Length of stay,
median (range), daysa 13 (1-251) 10.5 (1-122) 4 (1-62)
note. Data are no. (%) of patients, unless otherwise indicated. The re-
sistant case group consisted of patients from whom linezolid-resistant, van-
comycin-resistant Enterococcus (VRE) was isolated; the susceptible case group
consisted of patients from whom linezolid-susceptible VRE was isolated.
a for comparison of each case group’s length of stay with that ofP ! .001
the control group.
The defined daily dose (DDD) of linezolid was 1,200 mg.
Data were expressed as DDDs per 1,000 patient-days of bed
occupancy in the hospital.
Risk Factors Investigated
Data were collected by a comprehensive search of the mi-
crobiological and pharmacy databases, as well as electronic
patient records. The following variables were analyzed as po-
tential risk factors: patient demographic characteristics, co-
morbidities, use of a catheter, receipt of total parenteral nu-
trition (TPN), the patient’s location in the hospital, receipt
of recent corticosteroid therapy, previous linezolid exposure,
duration of linezolid exposure, and other recent antibiotic
exposure.
Corticosteroid use was analyzed for a 14-day period prior
to the isolation of the organism, in an attempt to confirm
previous reports that showed this to be a risk factor associated
with isolation of linezolid-resistant VRE.1 Antibiotic exposure
was analyzed for the 90-day period prior to recovery of the
isolate.
Case Definition, Control Definition, and Study Design
A case-case-control study design was used.17,18 In this study,
the same control group was used for the 2 concurrent retro-
spective case-control studies at the University of Pittsburgh
Medical Center, Presbyterian Hospital. This was considered the
appropriate control group selection, as both case groups were
from the same source population. Patients in the “resistant
case group” had enterococcal isolates that were resistant to
both linezolid and vancomycin (ie, linezolid-resistant VRE).
The patients in the “susceptible case group” had enterococcal
isolates that were resistant to vancomycin yet remained sus-
ceptible to linezolid (ie, linezolid-susceptible VRE).
The microbiology database was queried to identify all VRE-
positive culture samples obtained from patients at our insti-
tution from January 1, 2005, through June 30, 2006. Patients
who had enterococcal isolates recovered from routine screen-
ing cultures performed for surveillance purposes (eg, cultures
of rectal swab samples) were excluded from the study. The
information retrieved from the database was then analyzed
to find all patients from whom a linezolid-resistant VRE iso-
late had been recovered. Patients’ initial isolates were included
for analysis, and subsequent isolates were excluded. After
exclusions, 63 unique patients were selected for the resistant
case group. The initial data were then analyzed to identify
patients from whom linezolid-susceptible VRE had been re-
covered. This analysis found 247 unique patients, and 63
patients were randomly selected to make up the susceptible
case group. Furthermore, it was found that in our resistant
case group, 48 of the isolates were E. faecium and 15 were E.
faecalis; therefore, when randomly selecting the patients for
the susceptible case group, 48 were chosen from whom E.
faecium had been isolated and 15 were chosen from whom
E. faecalis had been isolated, to further match the groups.
The control group was randomly selected from patients who
were receiving care from the same medical or surgical services
as the case patients during the 18-month period of our study,
and control patients were excluded only if they had had an
enterococcal isolate recovered or if they had already been
selected as a control patient (patients could not be included
in the study more than once). The source population was
such that if a patient had a resistant enterococcal isolate re-
covered, that patient would have been eligible for a case
group. For each case patient, 2 control patients were selected,
yielding a total of 126 control patients.
Statistical Analysis
Potential risk factors associated with the isolation of linezolid-
resistant VRE were evaluated with SAS software, version 9.1
(SAS Institute). All categorical values were examined with the
SAS procedure “Genmod.” Continuous variables were ex-
amined by use of the nonparametric Wilcoxon test. All factors
were eligible for entry into the multivariate model. Uncon-
ditional multivariate stepwise logistic regression was per-
formed using the SAS procedure “Logistic,” with the entry
criteria set to 0.15 and the stay criteria set to 0.075.
Two simultaneous multivariate models were produced
from the data obtained. The first model compared the resis-
tant case group with the control group. The second model
compared the susceptible case group with this same control
group. Qualitative analysis between the 2 multivariate models
was then performed to determine specific risk factors asso-
ciated with the isolation of linezolid-resistant VRE.
results
During the 18-month study period, 63 unique patients had
linezolid-resistant VRE isolates recovered; overall, 20% of the
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table 2. Univariate Analysis of Risk Factors Associated With the Isolation of Line-
zolid-Resistant, Vancomycin-Resistant Enterococcus (VRE)
Variable
No. (%) of patients
OR (95% CI) P
Resistant
case groupa
(N p 63)
Control
group
(N p 126)
Male sex 29 (46) 69 (55) 0.70 (0.38-1.29) .26
White race 51 (81) 99 (79) 1.09 (0.46-2.58) .85
Location
Ward A 13 (21) 0 (0) 44.74 (7.24-) !.001
Ward B 3 (5) 0 (0) 7.91 (0.84-) .07
OSH 9 (14) 33 (26) 0.47 (0.21-1.06) .07
Nursing home 15 (24) 5 (4) 7.56 (2.60-21.96) !.001
Comorbidities
Diabetes 21 (33) 32 (25) 1.47 (0.76-2.84) .25
PVD 12 (19) 7 (6) 4.00 (1.49-10.75) .006
Receipt of an SOTb 30 (48) 8 (6) 13.41 (5.62-32.01) !.001
Receipt of TPNc 16 (25) 3 (2) 13.96 (3.89-50.11) !.001
Corticosteroid therapyd 32 (51) 26 (21) 3.97 (2.06-7.65) !.001
Antibiotic therapye
Cefazolin 29 (46) 53 (42) 1.17 (0.64-2,16) .60
Ribosomal antibioticsf 20 (32) 16 (13) 3.20 (1.52-6.74) .002
Linezolid 16 (25) 3 (2) 13.96 (3.89-50.11) !.001
Vancomycin 44 (70) 17 (14) 14.85 (7.07-31.19) !.001
Pip-Taz 33 (52) 12 (10) 10.45 (4.82-22.65) !.001
Cefepime 27 (43) 7 (6) 12.75 (5.13-31.71) !.001
Metronidazole 40 (64) 12 (10) 16.52 (7.53-36.24) !.001
Fluoroquinolones 27 (43) 10 (8) 8.70 (3.85-19.68) !.001
Carbapenems 23 (37) 4 (3) 17.54 (5.72-53.76) !.001
note. CI, confidence interval; OR, odds ratio; OSH, outside hospital; Pip-Taz, piperacillin-tazo-
bactam; PVD, peripheral vascular disease; SOT, solid organ transplant; TPN, total parenteral nutrition.
a Patients from whom linezolid-resistant VRE was isolated.
b Prior to isolation of linezolid-resistant VRE.
c At the time linezolid-resistant VRE was isolated.
d Within the 14 days prior to isolation of linezolid-resistant VRE.
e Within the 90 days prior to isolation of linezolid-resistant VRE.
f Macrolides, aminoglycosides, tetracyclines, quinupristin-dalfopristin, or clindamycin.
table 3. Multivariate Logistic Regression Analysis of Risk Factors
Associated With Isolation of Linezolid-Resistant, Vancomycin-
Resistant Enterococcus (VRE)
Risk factor OR (95% CI) P
Admission from a nursing home 12.7 (2.8-56.9) !.001
Peripheral vascular disease 12.4 (3.1-50.0) !.001
Receipt of a solid organ transplant 7.9 (2.3-27.5) .001
Receipt of TPN 7.2 (1.4-35.7) .016
Antibiotic therapya
Vancomycin 2.8 (0.9-8.6) .064
Piperacillin-tazobactam 5.6 (1.7-18.1) .004
Cefepime 4.2 (1.01-17.9) .049
Fluoroquinolones 3.4 (1.01-11.7) .048
note. Comparison of patients from whom linezolid-resistant VRE was
isolated and the control group. CI, confidence interval; OR, odds ratio; PVD,
peripheral vascular disease; TPN, total parenteral nutrition.
a In the 90 days before isolation of linezolid-resistant VRE.
VRE isolates analyzed were linezolid resistant. The most fre-
quent site of recovery was the urine (40% of resistant isolates).
Other major sites of recovery included wounds and/or ab-
scesses (28% of isolates), ascitic fluid (11% of isolates), re-
spiratory secretions (11% of isolates), and blood (5% of iso-
lates). Demographic characteristics were similar between the
case and control groups, with the exception of length of stay
(Table 1).
Linezolid use at our institution has steadily increased over
the past 5 years. The number of DDDs of linezolid per 1,000
patient-days in 2001 was 6.1; 10.1 in 2002; 11.1 in 2003; 12.7
in 2004; and during the study period, it was 17.4. The prev-
alence of linezolid resistance has likewise increased. In the
calendar years since linezolid susceptibility testing of enter-
ococcal isolates became routine, the susceptibility rate de-
creased from 85.1% of isolates in 2005 to 83.6% of isolates
in 2006.
The univariate analysis for risk factors associated with the
isolation of linezolid-resistant VRE is shown in Table 2, and
the corresponding multivariate analysis is shown in Table 3.
The univariate analysis for risk factors associated with the iso-
lation of linezolid-susceptible VRE is shown in Table 4, and
the corresponding multivariate analysis is shown in Table 5.
The multivariate logistic regression model showed that the
following independent risk factors were associated with the
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table 4. Univariate Analysis of Risk Factors Associated With Isolation of Linezolid-
Susceptible, Vancomycin-Resistant Enterococcus (VRE)
Risk factor
No. (%) of patients
OR (95% CI) P
Susceptible
case groupa
(N p 63)
Control
group
(N p 126)
Male sex 26 (41) 69 (55) 0.58 (0.31-1.07) .082
White race 50 (85) 99 (79) 1.07 (0.43-2.53) .88
Location
Ward A 7 (11) 0 (0) 21.09 (3.09-) .001
Ward B 7 (11) 0 (0) 21.09 (3.09-) .001
OSH 17 (27) 33 (26) 1.04 (0.53-2.06) .91
Nursing home 18 (29) 5 (4) 9.68 (3.39-27.61) !.001
Comorbidities
Diabetes 30 (48) 32 (25) 2.67 (1.41-5.05) .003
PVD 8 (13) 7 (6) 2.47 (0.85-7.16) .095
Receipt of an SOTb 21 (33) 8 (6) 7.37 (3.04-17.91) !.001
Receipt of TPNc 7 (11) 3 (2) 5.12 (1.28-20.55) .021
Corticosteroid therapyd 22 (36) 26 (21) 2.06 (1.05-4.05) .035
Antibiotic therapye
Cefazolin 23 (37) 53 (42) 0.79 (0.42-1.48) .46
Ribosomal antibioticsf 24 (38) 16 (13) 4.23 (2.04-8.78) .001
Linezolid 7 (11) 3 (2) 5.12 (1.28-20.55) .021
Vancomycin 43 (68) 17 (14) 13.79 (6.60-28.80) !.001
Pip-Taz 27 (43) 12 (10) 7.12 (3.28-15.49) !.001
Cefepime 24 (38) 7 (6) 10.46 (4.18-26.15) !.001
Metronidazole 37 (59) 12 (10) 13.52 (6.21-29.44) !.001
Fluoroquinolones 32 (51) 10 (8) 11.97 (5.31-27.00) !.001
Carbapenems 18 (29) 4 (3) 12.20 (3.92-38.00) !.001
note. CI, confidence interval; OR, odds ratio; OSH, outside hospital; Pip-Taz, piperacillin-tazo-
bactam; PVD, peripheral vascular disease; SOT, solid organ transplant; TPN, total parenteral nutrition.
a Patients from whom linezolid-susceptible, vancomycin-resistant Enterococcus (VRE) was recovered.
b Prior to isolation of linezolid-susceptible VRE.
c At the time linezolid-susceptible VRE was isolated.
d Within the 14 days prior to isolation of linezolid-susceptible VRE.
e Within the 90 days prior to isolation of linezolid-susceptible VRE.
f Macrolides, aminoglycosides, tetracyclines, quinupristin-dalfopristin, or clindamycin.
table 5. Multivariate Logistic Regression Analysis of Risk Factors
Associated With the Isolation of Linezolid-Susceptible, Vancomycin-
Resistant Enterococcus (VRE)
Risk factor OR (95% CI) P
Admission from a nursing home 7.4 (1.9-28.5) .004
Antibiotic therapy
Vancomycin 7.0 (2.7-18.0) !.001
Metronidazole 5.5 (2.0-15.0) !.001
Fluoroquinolones 9.6 (3.5-26.3) !.001
Ceftriaxone 8.5 (1.04-70.1) .046
note. Comparison of patients from whom linezolid-susceptible VRE was
isolated and the control group. CI, confidence interval; OR, odds ratio.
isolation of linezolid-resistant VRE: admission from a nursing
home (odds ratio [OR], 12.7 [95% confidence interval {CI},
2.8-56.9]), receipt of TPN at the time the isolate was recovered
(OR, 7.9 [95% CI, 1.4-35.7]), receipt of a solid organ trans-
plant (OR, 7.9 [95% CI, 2.3-27.5]), and peripheral vascular
disease (OR, 12.4 [95% CI, 3.1-50.0]). Receipt of any of the
following antibiotics was also an independent risk factor
associated with isolation of this organism: piperacillin-
tazobactam (OR, 5.6 [95% CI, 1.7-18.1]), cefepime (OR, 4.2
[95% CI, 1.01-17.9]), or fluoroquinolones (OR, 3.4 [95% CI,
1.01-11.7]).
Table 5 shows that admission from a nursing home was
also a risk factor associated with isolation of linezolid-sus-
ceptible VRE (OR, 7.4 [95% CI, 1.9-28.5]). Receipt of any
of the following antibiotics was an independent risk factor
associated with isolation of this organism: vancomycin (OR,
7.0 [95% CI, 2.7-18.0]), metronidazole (OR, 5.5 [95% CI,
2.0-15.0]), fluoroquinolones (OR, 9.6 [95% CI, 3.5-26.3]), or
ceftriaxone (OR, 8.5 [95% CI, 1.04-70.1])
Risk factors found to be specifically associated with iso-
lation of linezolid-resistant VRE were receipt of a solid organ
transplant, receipt of TPN, peripheral vascular disease, and
receipt of piperacillin-tazobactam or cefepime. Risk factors
that were only seen to be associated with the isolation of
linezolid-susceptible VRE were the receipt of vancomycin,
metronidazole, or ceftriaxone. Admission from a nursing
home and receipt of a fluoroquinolone were risk factors as-
sociated with isolation of both linezolid-resistant VRE and
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linezolid-susceptible VRE. Receipt of linezolid was not a risk
factor associated with isolation of linezolid-resistant VRE.
discussion
In this study we assessed risk factors associated with the iso-
lation of both linezolid-resistant VRE and linezolid-suscep-
tible VRE. To the best of our knowledge, this study examined
the largest sample of individuals from whom linezolid-resis-
tant VRE was isolated ( ) to date and is the first case-np 63
case-control analysis of associated risk factors. This meth-
odology ensures that the importance of previous antibiotic
exposure will not be overestimated (as is seen in a case-control
study in which uninfected patients serve as the control group)
and that the importance of horizontal transmission will not
be lost (as is seen in a case-control study in which patients
from whom the sensitive organism has been isolated serve as
the control group).17-21
Despite increased linezolid usage, international surveillance
data still show a relatively low incidence of linezolid-resistant
Enterococcus, with a prevalence rate of 2% or less, and reports
of linezolid-resistant VRE are limited to case reports and
institutional outbreaks.1-6,11-12,20-23 However, in our hospital,
microbiological data showed a much higher prevalence of
linezolid resistance among Enterococcus isolates, at 9.8%, and
in this study we found the prevalence of linezolid resistance
among VRE isolates to be 20%. A potential explanation for
this would be the much higher and continually increasing
rate of linezolid usage at our institution, compared with the
national average (17.4 vs 6.3 DDD per 1,000 patient-days).24,25
However, this explanation does not correlate with the re-
sults of our multivariate model, which favored horizontal
transmission of the resistant organism throughout our insti-
tution. In the multivariate model, receipt of a solid organ
transplant was a risk factor specifically associated with the
isolation of linezolid-resistant VRE, and this is most likely
due to the fact that the majority of our transplantation pa-
tients are located in the same ward in our institution. In the
univariate model, location in the transplantation ward at our
institution (ward A) was associated with an OR of 44.74 (95%
CI, 7.24-) for isolation of linezolid-resistant VRE. Presum-
ably this was not apparent in the multivariate model because
these patients shared the variable of having received a solid
organ transplant, which proved to be a significant, indepen-
dent risk factor.
Horizontal transmission of the organism is further sup-
ported by the fact that linezolid exposure was not an inde-
pendent risk factor associated with isolation of linezolid-re-
sistant VRE in the multivariate model. Although linezolid
exposure was found to be significant in both univariate mod-
els, the odds ratio was lower than that for exposure to many
other antibiotics. Furthermore, the duration of linezolid ex-
posure was not significantly longer in patients from whom
linezolid-resistant VRE was isolated, compared with control
patients (17 vs 13 days; ). These findings are consis-Pp .82
tent with a recent report of nosocomial spread of linezolid-
resistant VRE in which only 6 (15%) of 40 patients from
whom the resistant isolate was recovered had previous ex-
posure to linezolid. Pulsed-field gel electrophoresis patterns
in that report also showed clonally related isolates.22 Addi-
tional studies support the probability that linezolid-resistant
Enterococcus or linezolid-resistant VRE can be acquired by
nosocomial transmission.5,7-12 Our results, as well as these
findings, downplay the initial reports that showed that li-
nezolid-resistant VRE was only isolated from patients who
not only were exposed to linezolid but also underwent treat-
ment of long duration.
The identification of therapy with any of several antibiotics
as an independent risk factor is consistent with findings in
the literature regarding other resistant organisms, including
VRE. Antibiotic exposures that were found in this study to
be independent unique risk factors associated with the iso-
lation of linezolid-resistant VRE were receipt of piperacillin-
tazobactam and receipt of cefepime. Although selection pres-
sure for Enterococcus would be a plausible explanation, it does
not explain why exposures to these antibiotics would not also
select for linezolid-susceptible VRE. Since the majority of our
patients from whom linezolid-resistant VRE was isolated were
more critically ill, their exposure to broad-spectrum antibi-
otics may simply be a reflection of the complex nature of
their cases. Therefore, the identification of exposures to these
antibiotics as independent risk factors may simply be the
result of increased usage of these drugs for other indications,
with no direct effect on the enterococcal isolates themselves.
Corticosteroid usage in the past 14 days was examined as
a potential risk factor on the basis of a previous report that
showed an association between steroid usage and isolation of
linezolid-resistant VRE.1 Our current study showed that al-
though there was an association in the univariate model, this
was not seen in the multivariate model. Furthermore, a sim-
ilar association was also seen in the univariate model for the
isolation of linezolid-susceptible VRE. These findings show
that steroid use was more a common variable for all patients
from whom VRE was isolated, rather than a risk factor specific
for the isolation of linezolid-resistant VRE.
In evaluating antibiotic exposures, the choice of a 90-day
period was based on the nature of the organism in question.
Enterococcus species are known to colonize human beings for
extended periods of time. We felt it was appropriate to look
at an extended exposure period for the antibiotics that were
being considered. The reasons that we did not look at a time
period greater than 90 days, or even whether a patient ever
received linezolid, were that fact that 90 days was a common
duration in previous risk-factor studies and our own concerns
about the ability to accurately capture those specific data over
longer periods. Lastly, exposures to antibiotics that acted on
the bacterial ribosome were pooled together in the risk anal-
ysis because of a recent study that identified a plasmid-me-
diated transferable rRNA methyltransferase in Staphylococcus
aureus.26 Although this has not been identified in Enterococcus
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species, the transfer of other genetic material between these
2 bacteria has been described.
Length of stay (ie, time at risk) was also significantly higher
in both the resistant case group (13 vs 4 days; ) andP X .001
the susceptible case group (10 vs 4 days; ), comparedP X .001
with the control group. For case patients, time at risk was
considered the period prior to isolation Enterococcus in clin-
ical culture, and for control patients, it was the complete
length of hospital stay.18 This is not a surprising finding as
increased length of stay is a well-known risk factor for iso-
lation of resistant organisms, and it further emphasizes the
importance of horizontal transmission as an explanation for
the isolation of linezolid-resistant VRE.
There are important limitations to our study. The first is
that its retrospective nature meant that the linezolid-resistant
VRE isolates were unavailable for analysis. Lack of access to
these isolates makes confirmation of horizontal transmission
impossible, because pulsed-field gel electrophoresis could not
be performed. A second limitation was the inability to ensure
completeness in the records of outpatient antibiotic therapy
received. Although progress notes were analyzed in depth to
identify the antibiotics that were prescribed to patients as
outpatients, we cannot be certain that these notes were com-
prehensive. Therefore, there is a possibility that patients were
treated with oral linezolid in the community.
A third potential limitation to our study lies in the selection
of the control group, as previous studies have excluded pa-
tients whose hospital stay was 48 hours or less.17-20 We decided
against doing this because we noted that, in the resistant case
group, 12 patients had the organism isolated during the first
2 days of their hospital stay; that is, their time at risk was
less than 48 hours. We felt that if we had excluded these
patients from our control group it would have subtracted
from the accuracy of our source population.
The results of our study are consistent with the conclusion
that there is horizontal transmission of linezolid-resistant
VRE throughout our institution. As a result, all linezolid-
resistant VRE isolates are now retained and a follow-up mo-
lecular epidemiologic investigation will be performed in an
attempt to confirm this hypothesis. Also, the hospital’s Di-
vision of Infection Control has been made aware of our find-
ings. The hope is that these findings will further improve
compliance with contact isolation measures in our hospital,
because our employees will understand the high prevalence
rates of these highly resistant organisms and the primary
mechanism for transmission. At our institution, VRE sur-
veillance rectal swab samples are currently obtained once per
week, and patients with cultures positive for VRE are placed
under contact isolation precautions. All healthcare profes-
sionals must wash their hands before entering and after ex-
iting these rooms, and the use of gowns and gloves is required.
Education programs aimed at ensuring understanding and
compliance with these isolation measures have been previ-
ously implemented by the Division of Infection Control. Fur-
thermore, empirical therapy for patients from whom VRE is
isolated will take into account this high prevalence of linezolid
resistance. For patients with risk factors for acquisition of
linezolid-resistant VRE, the antibiotic management program
at our institution will suggest alternatives such as daptomycin
to treat bloodstream infections and endocarditis, doxycycline
to treat urinary tract infections, and tigecycline to treat intra-
abdominal infections.
In conclusion, our findings of the risk factors associated
with isolation of linezolid-resistant VRE, suggest that hori-
zontal transmission of this organism is common. Risk factors
specifically associated with the isolation of linezolid-resistant
VRE include the receipt of a solid organ transplant, receipt
of TPN, peripheral vascular disease, and exposure to piper-
acillin-tazobactam or cefepime. Furthermore, our study has
shown that the prevalence of linezolid-resistant VRE in our
institution is much higher than previously reported, and that
in such circumstances linezolid may be inappropriate for em-
pirical therapy for bloodstream infections suspected to be
caused by VRE.
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